Institute for Clinical and Economic Review Report Finds Evidence Inadequate to Distinguish the Clinical Benefits of Different Antiandrogen Therapies for Men with Nonmetastatic Castration-Resistant Prostate Cancer
Final Value Assessment Framework for 2017-2019
Following a public comment period on proposed changes to the framework, ICER has posted a final updated value assessment framework for 2017-2019.Learn More
Including the Patient Perspective
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.